RBC Capital Upgrades ResMed to Outperform, Raises Price Target to $284
Portfolio Pulse from richadhand@benzinga.com
RBC Capital analyst Craig Wong-Pan has upgraded ResMed (NYSE:RMD) from Sector Perform to Outperform and raised the price target from $262 to $284.
August 01, 2023 | 9:27 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ResMed's stock has been upgraded to Outperform by RBC Capital, with a raised price target of $284.
The upgrade from RBC Capital is a positive signal for ResMed. The raised price target indicates that the analyst sees potential for the stock's price to increase in the short term. This could lead to increased investor interest and potentially a rise in the stock's price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100